Survodutide
Also known as: BI 456906
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Pricing for Survodutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Survodutide
12 third-party tests across 3 vendors. Each card links to the full report.
For
Survodutide
by Real Peptides· batch Clear Cap/Purple Crimp
For
Survodutide
by Skye Peptides· batch SV25-12-001
For
Survodutide
by Skye Peptides· batch SV25-06-001
For
Survodutide
by Profound Aminos· batch 2025-01-23
For
Survodutide
by Hydro Research Peptides· batch 2024-08-05
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
29 citations indexed for Survodutide
Study · 2026
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial
Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist with the potential to induce greater weight reductions than GLP-1R mono-agonists.
Study · 2026
Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis
Background Metabolism-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide.
Study · 2026
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation
Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist in clinical development for people with obesity and people with metabolic dysfunction-associated steatohepatitis (MASH).
meta-analysis · 2026
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Introduction Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects.
Study · 2026
A review of survodutide: a new dual acting agonist
Survodutide represents an innovative approach to obesity management and metabolic-associated fatty liver disease (MAFLD). These conditions, often closely linked with type 2 diabetes (T2DM) and cardiovascular diseases, demand effective treatment strategies.
review · 2026
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Glucagon-like-peptide-1 receptor (GLP-1R) agonists are under development as new drugs to treat type 2 diabetes, liver disease, obesity and cardiovascular diseases. Some of these drugs are solely agonists of the GLP-1R.